What is Zacks Research’s Forecast for COO Q3 Earnings?

The Cooper Companies, Inc. (NASDAQ:COO) – Investment analysts at Zacks Research boosted their Q3 2025 earnings estimates for shares of Cooper Companies in a research report issued to clients and investors on Tuesday, December 24th. Zacks Research analyst I. Bandyopadhyay now expects that the medical device company will post earnings of $1.05 per share for the quarter, up from their prior estimate of $1.04. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share. Zacks Research also issued estimates for Cooper Companies’ FY2025 earnings at $3.98 EPS, Q1 2026 earnings at $1.02 EPS, Q2 2026 earnings at $1.06 EPS, Q3 2026 earnings at $1.15 EPS, Q4 2026 earnings at $1.19 EPS, FY2026 earnings at $4.42 EPS and FY2027 earnings at $4.86 EPS.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Thursday, December 5th. The medical device company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.04. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.03 billion. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.87 EPS.

Several other equities research analysts have also recently weighed in on the company. Morgan Stanley decreased their target price on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a research note on Friday, December 6th. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research report on Friday, December 6th. StockNews.com downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Citigroup cut their price target on shares of Cooper Companies from $116.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, December 6th. Finally, Wells Fargo & Company upped their price objective on shares of Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, Cooper Companies has a consensus rating of “Moderate Buy” and a consensus target price of $117.00.

Cooper Companies Stock Performance

Shares of Cooper Companies stock opened at $92.34 on Friday. The business has a 50-day simple moving average of $100.66 and a 200-day simple moving average of $98.82. The company has a market cap of $18.43 billion, a PE ratio of 47.35, a P/E/G ratio of 2.52 and a beta of 0.97. Cooper Companies has a one year low of $84.76 and a one year high of $112.38. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91.

Institutional Trading of Cooper Companies

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its stake in Cooper Companies by 13.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company’s stock valued at $543,979,000 after buying an additional 573,908 shares during the period. Principal Financial Group Inc. raised its holdings in Cooper Companies by 6.6% during the third quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company’s stock worth $26,295,000 after purchasing an additional 14,687 shares in the last quarter. Lord Abbett & CO. LLC lifted its position in Cooper Companies by 6.3% in the third quarter. Lord Abbett & CO. LLC now owns 251,402 shares of the medical device company’s stock valued at $27,740,000 after purchasing an additional 14,957 shares during the period. Franklin Resources Inc. boosted its holdings in Cooper Companies by 194.0% in the 3rd quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company’s stock valued at $5,265,000 after purchasing an additional 32,260 shares in the last quarter. Finally, Synovus Financial Corp increased its position in Cooper Companies by 18.8% during the 3rd quarter. Synovus Financial Corp now owns 31,568 shares of the medical device company’s stock worth $3,483,000 after purchasing an additional 4,987 shares during the period. 24.39% of the stock is owned by hedge funds and other institutional investors.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.